Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition

An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Effect on Blood Lipid Profiles of Omega-3 Enriched Total Parenteral Nutrition in Healthy Korean Male Subjects

Fish oil is a rich source of omega-3 fatty acids, especially eicosapentanoic acid and docosahexaenoic acid, and it is not used widely in parenteral nutrition because fish oil emulsions have not been commercially available until very recently. The Objective of this study is to to evaluate the effect on blood lipid profiles of omega-3 enriched total parenteral nutrition in healthy Korean male subjects. This study is designed as a randomized, open-label, 2-treatment, 2-way crossover trial. Blood samples will be collected every 1 hour from 0 to 12 hours after starting an intravenous infusion for triglyceride, glucose, and insulin.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Combiflex® lipid peri; Drug: Winuf® peri

Detailed Description

Fish oil is a rich source of omega-3 fatty acids, especially eicosapentanoic acid and docosahexaenoic acid, and it is not used widely in parenteral nutrition because fish oil emulsions have not been commercially available until very recently. The Objective of this study is to to evaluate the effect on blood lipid profiles of omega-3 enriched total parenteral nutrition in healthy Korean male subjects.

This study is designed as a randomized, open-label, 2-treatment, 2-way crossover trial. The 16 subjects will be randomly assigned to 1 of 2 sequences of the two treatments: Combiflex® lipid peri or Winuf® peri will be infused via peripheral venous catheter for 6 hours at 3 ml/kg/h. Blood samples will be collected every 1 hour from 0 to 12 hours after starting an intravenous infusion for triglyceride, glucose, and insulin. Cholesterol, HDL-cholesterol, LDL-cholesterol, AST, ALT, and total bilirubin as liver function biomarkers, and hsCRP as inflammatory biomarker will be analysed at 0, 6 and 12 hour after starting an intravenous infusion.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 4

Contacts and Locations

Study Locations

• Korea, Republic of
  • Jeonbuk
    • Jeonju, Jeonbuk, Korea, Republic of, 561712
      • Chonbuk National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 28 years to 53 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy male subjects between the ages of 30 and 55 years
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg
• An informed consent document signed and dated by the subject
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
• Screening sitting blood pressure >150 mm Hg (systolic) or >90 mm Hg (diastolic)
• Use of tobacco in excess of the equivalent of 20 cigarettes per day
• Use of prescription or nonprescription drugs within 10 days
• Blood donation within 2 months prior to dosing, or plasma donation within 1 month prior to dosing
• Severe hyperlipidemic patients
• Severe liver failure patients

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)	Drug: Combiflex® lipid peri; total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil; Drug: Winuf® peri; total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
Experimental: Group 2; Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)	Drug: Combiflex® lipid peri; total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil; Drug: Winuf® peri; total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare AUC of plasma triglyceride between Winuf peri and Combiflex lipid peri	The wash-out period will be 7 days, and the second study period will be conducted on the same schedule as the first study period, with the exception of the assignment of the investigational product.	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare Cmax of plasma triglyceride between Winuf peri and Combiflex lipid peri	The wash-out period will be 7 days, and the second study period will be conducted on the same schedule as the first study period, with the exception of the assignment of the investigational product.	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing

Secondary Outcome Measures

Outcome Measure	Time Frame
To compare AUC of plasma glucose between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare Cmax of plasma glucose between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare AUC of plasma insulin between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare Cmax of plasma insulin between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare AUC of plasma omega-3 between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
To compare Cmax of plasma omega-3 between Winuf peri and Combiflex lipid peri	Before-dosing(0 hour) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours after dosing
Change from baseline in blood cholesterol level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood HDL-cholesterol level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood LDL-cholesterol level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood AST level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood ALT level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood total bilirubin level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours
Change from baseline in blood hsCRP level at 6 and 12 hours	Before-dosing(0 hour) and 6, and 12 hours

Collaborators and Investigators

• Sponsor: Chonbuk National University Hospital
• Collaborators: JW Pharmaceutical
• Investigators: Principal Investigator: Hee Chul Yu, MD, PhD, professor

Study record dates

Study Major Dates

• Study Start: January 1, 2015
• Primary Completion (Actual): April 1, 2015
• Study Completion (Actual): April 1, 2015

Study Registration Dates

• First Submitted: May 29, 2015
• First Submitted That Met QC Criteria: June 8, 2015
• First Posted (Estimate): June 11, 2015

Study Record Updates

• Last Update Posted (Estimate): June 11, 2015
• Last Update Submitted That Met QC Criteria: June 8, 2015
• Last Verified: June 1, 2015

More Information

Terms related to this study

• Keywords: Insulin; DHA; Omega-3; Glucose; Triglyceride; LDL; EPA; Blood lipid profiles; TPN
• Other Study ID Numbers: CUH201412002